Literature DB >> 23603461

Protective effect of magnesium lithospermate B against dextran sodiumsulfate induced ulcerative colitis in mice.

Xiaoyun Jiang1, Yibin Jiang, Dayu Sun, Lan Rong.   

Abstract

Anti-platelet drugs have been used to treat inflammatory bowel disease. In this study, we observed the therapeutic effects of magnesium lithospermate B, a main component of salvianolate, on colitis induced by dextran sodiumsulfate (DSS). Colitis was induced by 5% DSS oral administration in BALB/C male mice. Magnesium lithospermate B (60-240mg/kg) was given by subcutaneous injection for 2 weeks. Then, mice were sacrificed; serum and colon tissues were collected for biomarker assay, histological examination, immunohistochemical study and real-time quantitative polymerase chain reaction. DSS induced gross bleeding, inflammation, crypt damage and mucosal damage in colon. Treatment with magnesium lithospermate B could reduce colon inflammation induced by DSS. Magnesium lithospermate B could reverse the high CD40/CD40L expression and hypercoagulable state induced by DSS in colon. This study showed that magnesium lithospermate B could be used to treat colitis. The protective effects of magnesium lithospermate B may be due to its effects on CD40/CD40L expression and blood clotting status.
Copyright © 2013 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23603461     DOI: 10.1016/j.etap.2013.03.010

Source DB:  PubMed          Journal:  Environ Toxicol Pharmacol        ISSN: 1382-6689            Impact factor:   4.860


  2 in total

Review 1.  Salvia miltiorrhiza Bge. (Danshen) for Inflammatory Bowel Disease: Clinical Evidence and Network Pharmacology-Based Strategy for Developing Supplementary Medical Application.

Authors:  Siyuan Zhang; Hua Luo; Shiyi Sun; Yating Zhang; Jiaqi Ma; Yuting Lin; Lin Yang; Dechao Tan; Chaomei Fu; Zhangfeng Zhong; Yitao Wang
Journal:  Front Pharmacol       Date:  2022-01-19       Impact factor: 5.810

2.  Magnesium Lithospermate B Protects against Lipopolysaccharide-Induced Bone Loss by Inhibiting RANKL/RANK Pathway.

Authors:  Jihai Wang; Xuejian Wu; Yongzhuang Duan
Journal:  Front Pharmacol       Date:  2018-02-06       Impact factor: 5.810

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.